Janssen Faces Mixed Prospects In Immuno Drug IP Suit
A federal judge in Boston on Tuesday gave good news to both Janssen Biotech and Celltrion Healthcare in their dispute over a biosmilar version of Janssen's $4 billion-a-year immunosuppressant drug, saying...To view the full article, register now.
Already a subscriber? Click here to view full article